{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:16:21Z","timestamp":1795032981431,"version":"4.10.2"},"reference-count":93,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Molecular genetic analysis adds important information for lymphoma biology and classification, but the latter is challenged by recent improvement of combined chemo\u2010immunotherapy. In aggressive lymphoma, molecular profiling identifies risk groups with certain genetic background but still the International Prognostic Index (IPI) remains the most important clinically applicable predictor of outcome. In follicular lymphoma (FL), the importance of the meshwork of bystander cells becomes increasingly evident. As combined immuno\u2010chemotherapy improved the prognosis of the patients, several clinical trials indicated that the FLIPI still efficiently discriminates patients at risk for transformation and relapse, although several mechanisms of transformation seem to exist. In mantle cell lymphoma it has been proven that pathogenesis and prognosis mainly depend on deregulation of the cell cycle. A reliable clinical risk score could be established.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07138.x","type":"journal-article","created":{"date-parts":[[2008,5,19]],"date-time":"2008-05-19T13:44:06Z","timestamp":1211204646000},"page":"166-178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling"],"prefix":"10.1111","volume":"142","author":[{"given":"B.","family":"Gleissner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"K\u00fcppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"433A","DOI":"10.1182\/blood.V106.11.1504.1504","article-title":"A phase I study of humanized anti\u2010CD40 immunotherapy with SGN\u201040 in non\u2010Hodgkin\u2019s lymphoma","volume":"106","author":"Advani R.H.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_8_4_1","first-page":"1605","article-title":"The presence of STAT1\u2010positive tumor\u2010associated macrophages and their relation to outcome in patients with follicular lymphoma","volume":"91","author":"Alvaro T.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1399"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1309\/TNKL7GDC66R9WPV5"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.12.005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402568"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"},{"key":"e_1_2_8_12_1","first-page":"803A","article-title":"Pharmaco kinetics and pharmacodynamics from a first\u2010in\u2010human phase 1 dose escalation study with antagonist anti\u2010CD40 antibody, HCD122 (formerly CHIR\u201012.12), in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"108","author":"Byrd J.C.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"822a","DOI":"10.1182\/blood.V108.11.822.822","article-title":"The poor prognosis value of high intra\u2010tumoral macrophages counts in follicular lymphoma patients requires selection of appropriate cut\u2010off and can be circumvented by rituximab therapy","volume":"108","author":"Canioni D.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018218"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.054"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041869"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.26.856"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4490"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"273A","DOI":"10.1182\/blood.V106.11.929.929","article-title":"Primary mediastinal large B\u2010cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)\u2010EPOCH and overcomes the need for radiation","volume":"106","author":"Dunleavy K.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.6840"},{"key":"e_1_2_8_24_1","first-page":"2291","article-title":"Subclassification of diffuse large B\u2010cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor","volume":"89","author":"Engelhard M.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1565"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"766A","DOI":"10.1182\/blood.V108.11.2711.2711","article-title":"Clinical activity of the immunoconjugate CMC\u2010544 in B\u2010Cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study","volume":"108","author":"Fayad L.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1753"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0015"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2298"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"598S","DOI":"10.1200\/jco.2005.23.16_suppl.6654","article-title":"Dose escalated CHOP plus etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL","volume":"23","author":"Glass B.","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880035"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00995.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1526"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10314"},{"key":"e_1_2_8_41_1","article-title":"A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma","volume":"108","author":"Hoster E.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055351"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4264"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402707"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood.V86.10.3905.bloodjournal86103905","article-title":"Cytogenetic evolution patterns in non\u2010Hodgkin\u2019s lymphoma","volume":"86","author":"Johansson B.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63313-5"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4079"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-026344"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706828"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5833"},{"key":"e_1_2_8_51_1","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1182\/blood.V86.10.3930.bloodjournal86103930","article-title":"Analysis of rearranged T\u2010cell receptor beta\u2010chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis","volume":"86","author":"Kneba M.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364364"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111948"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4642"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm114"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032520"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02317.x"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22342"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3442"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047068"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3806"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034173"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_2_8_66_1","doi-asserted-by":"crossref","first-page":"916A","DOI":"10.1182\/blood.V106.11.3275.3275","article-title":"Quantitative assessment of molecular remission following autologous stem cell transplantation predicts long term remission in mantle cell lymphoma","volume":"106","author":"Pott C.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04802.x"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-110072"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2490"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404594"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.3063.3063"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.21.9638"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0041"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1841"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.7689"},{"key":"e_1_2_8_79_1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V83.5.1165.1165","article-title":"Prognostic factors in aggressive non\u2010Hodgkin\u2019s lymphoma: who has \u201chigh\u2010risk\u201d disease?","volume":"83","author":"Shipp M.A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-68"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6291"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0542"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_8_85_1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V84.4.1043.1043","article-title":"Prognostic value of chromosomal abnormalities in follicular lymphoma","volume":"84","author":"Tilly H.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0487"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1986"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6610211"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.006"},{"key":"e_1_2_8_90_1","first-page":"160A","article-title":"Preliminary results from a phase II study of lenalidomide monotherapy in relapsed\/refractory aggressive non\u2010Hodgkin\u2019s lymphoma","volume":"108","author":"Wiemik P.H.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-039859"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4222"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.005"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07138.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07138.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T15:30:30Z","timestamp":1697383830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07138.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,28]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07138.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07138.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,28]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}